

IN THE CLAIMS:

Please enter the following amended claims:

1. (Currently amended) A substantially ~~Substantially~~-purified form of a the polypeptide, said polypeptide ~~that~~ comprising the amino acid ~~amino acid~~-sequence shown in SEQ ID NO. 13 or 14, a homologue thereof, a fragment thereof or a homologue of the fragment.

C1 2. (Currently amended) The A-polypeptide according to claim 1, said polypeptide ~~comprising that consists (comprising)~~ of the amino acid ~~amino acid~~-sequence shown in SEQ ID NO. 13 or 14.

3. (Original) A cDNA encoding the polypeptide according to claim 1.

4. (Currently amended) The A-cDNA according to claim 3, said cDNA ~~that~~ comprising the nucleotide sequence shown in SEQ ID NO. 11 or 15, or a fragment cDNA that selectively hybridizes ~~hybridized~~ to said ~~the~~-cDNA.

C2 5. (Currently amended) The A-cDNA according to claim 3, said cDNA ~~that~~ comprising the nucleotide sequence shown in SEQ ID NO. 12, or a fragment cDNA that selectively hybridizes ~~hybridized~~ to said ~~the~~-cDNA.

6. (Currently amended) A replication or expression vector carrying the cDNA according to any one of claims ~~claim~~ 3 to 5.

7. (Original) A host cell transformed with the replication or expression vector according to claim 6.

8. (Currently amended) A method for producing a the polypeptide, comprising ~~according to claim 1 or 2 which comprises~~ culturing a host cell according to claim 7 under a

condition effective to express ~~a the polypeptide encoded by the cDNA according to claim 1 or 2,~~
and collecting the polypeptide encoded by the cDNA.

9. (Original) A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.

10. (Currently amended) A pharmaceutical composition comprising a ~~containing the~~ polypeptide according to claim 1 or 2 ~~or the antibody according to claim 9,~~ in association with a pharmaceutically acceptable diluent and/or carrier.

11. (Currently amended) A pharmaceutical composition for ~~the treatment of~~ abnormal growth of a smooth muscle cell, comprising ~~containing a~~ polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier.

C1 12. (Currently amended) A pharmaceutical composition for ~~the treatment of~~ arteriosclerosis, restenosis after PTCA or myosarcoma, comprising a ~~containing the~~ polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier.

13. (Currently amended) A screening method for an antagonist or agonist of the polypeptide according to claim 1 or 2, comprising

a) contacting a cell with ~~with using the said polypeptide and a test compound,~~
b) determining a result on cell growth of said contact, and
c) comparing said result with a result from a control experiment where a cell is
contacted with the polypeptide in the absence of the test compound.

14. (Previously added) A method for promoting smooth muscle growth or vasculogenesis which comprises administering to a mammalian subject a therapeutically effective amount of an antibody of claim 9.

C1 15. (Previously added) A pharmaceutical composition for promoting smooth muscle cell growth or vasculogenesis which comprises administering to a mammalian subject a therapeutically effective amount of an antibody of claim 9.
